Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech, a clinical-stage company leveraging AI for vaccine development, has reported a promising first half of 2024, including a $15 million public offering and advancements in their AI-Immunology powered vaccine pipeline. The firm highlighted the progress of their EVX-01 Phase 2 trial for metastatic melanoma, with positive immune response data and a one-year readout anticipated in the third quarter. Evaxion remains focused on business development and is optimistic about potential partnerships that align with their goal to match yearly operational cash burn.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
